Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria
Sadayoshi Ito, Kenichi Shikata, Masaomi Nangaku, et al.
Clinical Journal of the American Society of Nephrology (2019) Vol. 14, Iss. 8, pp. 1161-1172
Open Access | Times Cited: 96

Showing 1-25 of 96 citing articles:

KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Peter Rossing, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2022) Vol. 102, Iss. 5, pp. S1-S127
Open Access | Times Cited: 693
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Rajiv Agarwal, Peter Kolkhof, George L. Bakris, et al.
European Heart Journal (2020) Vol. 42, Iss. 2, pp. 152-161
Open Access | Times Cited: 387
Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence
Peter Rossing, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2022) Vol. 102, Iss. 5, pp. 990-999
Open Access | Times Cited: 176
Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)
Sadayoshi Ito, Naoki Kashihara, Kenichi Shikata, et al.
Clinical Journal of the American Society of Nephrology (2020) Vol. 15, Iss. 12, pp. 1715-1727
Open Access | Times Cited: 170
Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects
Jonatan Barrera‐Chimal, Ixchel Lima‐Posada, George L. Bakris, et al.
Nature Reviews Nephrology (2021) Vol. 18, Iss. 1, pp. 56-70
Closed Access | Times Cited: 153
Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)
Sadayoshi Ito, Hiroshi Itoh, Hiromi Rakugi, et al.
Hypertension (2019) Vol. 75, Iss. 1, pp. 51-58
Open Access | Times Cited: 144
Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression
Sandra Naaman, George L. Bakris
Diabetes Care (2023) Vol. 46, Iss. 9, pp. 1574-1586
Open Access | Times Cited: 106
Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease
Edmund Y. M. Chung, Marinella Ruospo, Patrizia Natale, et al.
Cochrane library (2020) Vol. 2020, Iss. 10
Open Access | Times Cited: 111
Update on diagnosis, pathophysiology, and management of diabetic kidney disease
Mai Sugahara, Wai Lun Will Pak, Tetsuhiro Tanaka, et al.
Nephrology (2021) Vol. 26, Iss. 6, pp. 491-500
Open Access | Times Cited: 102
Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials
Ajay Chaudhuri, Husam Ghanim, Pradeep Arora
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 3, pp. 365-376
Open Access | Times Cited: 73
Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study
Takashi Wada, Masaya Inagaki, Toru Yoshinari, et al.
Clinical and Experimental Nephrology (2020) Vol. 25, Iss. 2, pp. 120-130
Open Access | Times Cited: 70
Stem cell-derived and circulating exosomal microRNAs as new potential tools for diabetic nephropathy management
Lei Peng, Yu Chen, Shaoqing Shi, et al.
Stem Cell Research & Therapy (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 42
Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease
Javier Morales, Yehuda Handelsman
Journal of the American College of Cardiology (2023) Vol. 82, Iss. 2, pp. 161-170
Open Access | Times Cited: 34
Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension
Hiromi Rakugi, Sadayoshi Ito, Hiroshi Itoh, et al.
Hypertension Research (2019) Vol. 42, Iss. 12, pp. 1932-1941
Open Access | Times Cited: 60
Recent Research Advances in Renin-Angiotensin-Aldosterone System Receptors
Kengo Azushima, Norihiko Morisawa, Kouichi Tamura, et al.
Current Hypertension Reports (2020) Vol. 22, Iss. 3
Closed Access | Times Cited: 60
Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease
Ningning Wan, Asadur Rahman, Akira Nishiyama
Journal of Human Hypertension (2020) Vol. 35, Iss. 2, pp. 148-156
Closed Access | Times Cited: 53
Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease
Alberto Ortíz, Charles J. Ferro, Olga Balafa, et al.
Nephrology Dialysis Transplantation (2021) Vol. 38, Iss. 1, pp. 10-25
Open Access | Times Cited: 48
Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)
Pantelis Sarafidis, Fotini Iatridi, Charles J. Ferro, et al.
Clinical Kidney Journal (2023) Vol. 16, Iss. 11, pp. 1885-1907
Open Access | Times Cited: 21
Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists
Christian W. Mende, Rohan Samarakoon, Paul J. Higgins
American Journal of Nephrology (2023) Vol. 54, Iss. 1-2, pp. 50-61
Open Access | Times Cited: 17
Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD
Xiaoling Luo, Jing Xu, Shoulian Zhou, et al.
Clinical Journal of the American Society of Nephrology (2023) Vol. 18, Iss. 8, pp. 1019-1030
Closed Access | Times Cited: 17
The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis
Reid Whitlock, Silvia J. Leon, Hazel Manacsa, et al.
Nephrology Dialysis Transplantation (2023) Vol. 38, Iss. 11, pp. 2503-2516
Open Access | Times Cited: 16
Role of mineralocorticoid receptor antagonists in kidney diseases
Vishal Patel, Amit Joharapurkar, Mukul R. Jain
Drug Development Research (2020) Vol. 82, Iss. 3, pp. 341-363
Closed Access | Times Cited: 49
Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction
Sadayoshi Ito, Hiroshi Itoh, Hiromi Rakugi, et al.
Hypertension Research (2020) Vol. 44, Iss. 5, pp. 489-497
Open Access | Times Cited: 46
Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics
Jonatan Barrera‐Chimal, Peter Kolkhof, Ixchel Lima‐Posada, et al.
Expert Opinion on Investigational Drugs (2021) Vol. 30, Iss. 11, pp. 1141-1157
Open Access | Times Cited: 37
Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks
Nathan Mullen, James Curneen, Padraig Donlon, et al.
Endocrine Reviews (2023) Vol. 45, Iss. 1, pp. 125-170
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top